-
Shanghai Henlius Biotech Announces Executive Leadership Changes
•
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced significant changes in its executive leadership. Zhang Wenjie, who has been instrumental in the company’s growth since joining in March 2019, has resigned from his position as CEO. Despite this change, Zhang will continue to contribute to Henlius Biotech as the…
-
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
•
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ: ARGX) have announced preliminary positive results from the ADHERE study. The study assessed the effects of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The ADHERE trial is the…
-
ObsEva SA Regains Full Rights to Nolasiban After Terminating Yuyuan Biological License Deal
•
Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights to its pipeline candidate, nolasiban, after the termination of a previous license agreement with China-based Yuyuan Biological Technology. Nolasiban’s Profile and Its Importance in IVF TreatmentNolasiban is an oral oxytocin receptor antagonist that plays a…
-
Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from a Phase III confirmatory study for the bispecific antibody Rybrevant (amivantamab). The study focused on patients with newly diagnosed advanced or metastatic non-small cell lung cancer (NSCLC) that harbor epidermal growth factor receptor (EGFR) exon…
-
Antengene Corp., Ltd Receives Hong Kong NDA Approval for Xpovio in Relapsed Multiple Myeloma
•
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced receiving New Drug Application (NDA) approval from the Department of Health of Hong Kong. The approval is for the use of Xpovio in adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least four prior…
-
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-A1811 and Pyrotinib Combo Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study. The study will assess the safety, tolerability, and efficacy of SHR-A1811 in combination with the small-molecule HER2 inhibitor pyrotinib for the treatment…
-
Shanghai Xinhengrui Medical Technology Secures Series A Funding for Heart Failure Device Development
•
Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised close to RMB 100 million (USD 13.95 million) in a Series A financing round. The round was led by IDG Capital, with additional investments from Hygeia Capital and Everest Capital. The funds will be directed…
-
Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline
•
Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology and oncology, has reportedly raised tens of millions of renminbi in a Pre-Series A financing round. The round was led by Ming Bioventures, with contributions from Highpower Industrial and 3D BioOptima. The funds will be…
